Literature DB >> 2953944

Evidence that the stimulus properties of apomorphine are mediated by both D1 and D2 receptor activation.

M D Schechter, N L Greer.   

Abstract

Male and female rats were trained to discriminate between the stimulus properties of apomorphine (0.16 mg/kg i.p.) and saline in a two-lever, food-motivated operant procedure. Apomorphine, at doses different than the training dose, produced a similar dose-dependent relationship in both sexes. Consistent with the hypothesis that the behavioral effects of apomorphine are mediated by D2 activation, the apomorphine interoceptive cue generalized to bromocriptine, a drug considered to be a preferential D2 agonist. In addition, the dose-response curve after 5-15 mg/kg bromocriptine administration was parallel to that of apomorphine. Consistent with the biochemical evidence that apomorphine's effects are mediated, to a lesser extent, by D1 activation, the apomorphine cue partially generalized to the selective D1 agonist SKF 38393. Furthermore, the apomorphine cue was not blocked by the selective D1 antagonist SCH 23390. Somewhat surprising was the partial generalization of the apomorphine cue to SCH 23390. However, this is not the first time that the administration of SCH 23390 has resulted in unexpected behavioral responses. Other novel findings include the lack of sex differences in acquisition training to the apomorphine cue and in the generalization tests to the selective agonists. The behavioral results are consistent with previous biochemical evidence that the effects of apomorphine are mediated by both D1 and D2 activation and is further behavioral support that apomorphine's effects are not the result of D2 activation alone, as previously hypothesized.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953944     DOI: 10.1016/0024-3205(87)90762-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Role of specific dopamine receptor subtypes in amphetamine discrimination.

Authors:  F L Smith; C St John; T F Yang; W H Lyness
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Behavioural supersensitivity following neonatal 6-hydroxydopamine: attenuation by MK-801.

Authors:  T Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

4.  Studies on the discriminative stimulus properties of apomorphine in rhesus monkeys.

Authors:  A H Tang; R A Code
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  The discriminative properties of the D1 dopamine agonist dihydrexidine in the rat.

Authors:  M D Schechter
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

Review 6.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.

Authors:  H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 7.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

8.  Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.

Authors:  Trevor Archer; Tomas Palomo; Robert McArthur; Anders Fredriksson
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

9.  Pretreatment or Posttreatment with Aripiprazole Attenuates Methamphetamine-induced Stereotyped Behavior in Mice.

Authors:  Nobue Kitanaka; Junichi Kitanaka; F Scott Hall; Masaru Kayama; Hironobu Sugimori; George R Uhl; Motohiko Takemura
Journal:  J Exp Neurosci       Date:  2015-09-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.